New strategy for cancer therapy spells double trouble for tumors Scripps Research scientists have found a clever way to combine two cellular defects and kill aggressive cancer cells.
July 25, 2018
Scientists at Scripps Research have uncovered a new strategy to kill tumors, including some triple-negative breast cancers, without harming healthy cells, a discovery that could lead to more ways to treat tumors while reducing side effects.
The study, published recently in Nature Communications, shows that a molecule in cells, called Rad52, repairs special kinds of damaged DNA that accumulate in some cancers. A future therapeutic could inhibit Rad52, robbing cancer cells of this repair mechanism.
This could give us a way to kill tumors without harming normal cells, says Xiaohua Wu, PhD, professor at Scripps Research and senior author of the study. That's the future. That's the goal for targeted cancer treatments to make these treatments a part of precision medicine.
Wu and her colleagues investigate how seemingly healthy cells become cancerous, with an eye toward leveraging differences between cancers and healthy cells to develop new therapeutic approaches. The culprits may be different from patient to patient, so the key to killing specific cancer types is to study the basic roles of proteins and how things go awry in different cancers.
The most important thing is to understand the defects in all these tumors, and then you can understand how to target them specifically, says Wu.
One cancer subtype is triple-negative breast cancer, which make up 10 to 20 percent of breast cancer diagnoses. This aggressive form strikes an estimated 28,000 Americans each year.
The new research shows how to exploit a weakness in some triple-negative breast cancers. Some of these tumors have a deficient version of the gene that codes for a protein called FANCM. Normally, this protein protects regions of DNA called common fragile sites, which are prone to breaking when cells divide.
Wu's team found that FANCM-deficient tumors have to call in a backup team to repair DNA. That's when the protein Rad52 steps in to repair DNA damage in these tumors. This finding came as a surprise because Rad52 plays no essential role in healthy cells.
Next, the researchers tested what would happen if they stopped Rad52 from working in FANCM-deficient cells. As they suspected, the cells accumulated double-strand breaks at common fragile sites. With no way to repair these breaks, the cells died. Follow-up experiments in a mouse model showed that suppressing Rad52 in FANCM tumors dramatically reduced cell and tumor growth.
This phenomenon, when a cell only dies because of a combination of two defects, is called synthetic lethality. Only cells with both defects will die. This means drugs inhibiting Rad52 would not harm healthy cells, which do have sufficient FANCM. Only FANCM-deficient cells, like those seen in some triple-negative breast cancers, would die.
Normal cells are fine when you remove Rad52, so we think potential therapies would have a very low toxicity, Wu says.
Exploiting synthetic lethality is emerging as a crucial strategy in cancer drug design. In fact, the U.S. Food and Drug Administration recently approved several drugs called PARP inhibitors, which also take advantage of synthetic lethality to kill tumors with BRCA mutations.
Wu says the next step in this project is to develop potent small molecule inhibitors of Rad52 that could be tested as a drug candidate for a new targeted cancer therapy. This study shows why it's very important to focus on basic research and then follow-up on findings that can benefit patients, Wu says.
Additional authors of the study, The concerted roles of FANCM and Rad52 in the protection of common fragile sites, were co-first authors Hailong Wang and Jianping Ren of Capital Normal University, Beijing; co-first author Shibo Li and Joshua Oaks of Scripps Research; and Lei Li of the M.D. Andersen Cancer Center.
The research was supported by the National Institutes of Health (grants CA187052, CA197995, GM080677, CA179441 and CA193124-Project 3), the National Basic Research Program of China (2015CB910602) and National Natural Science Foundation of China (31370841).
Cancer Molecular Medicine Wu, Xiaohua New therapies
Most recent headlines
11/12/2025
Dalet, a leading provider of cloud-native, end-to-end media workflow solutions, ...
06/12/2025
In a live broadcast from the Reagan National Defense Forum, L3Harris Chair and CEO Christopher Kubasik joined Morgan Brennan on CNBCs Closing Bell: Overtime. Ku...
06/12/2025
FORT LAUDERDALE, Fla. A new survey from Pixitmedia by Datacore revealed a major shift in the Media & Entertainment industry in media archiving, with 85% of resp...
06/12/2025
HACKENSACK, N.J. LiveU has announced that the national public broadcaster Czech Television has completed one of the largest LiveU live production deployments fo...
06/12/2025
NEW YORK The National Academy of Television Arts and Sciences (NATAS) presented the Excellence in Production Technology Emmy Award to NASA+ and Dr. Tom Leight...
05/12/2025
2025 Sports Broadcasting Hall of Fame: Curt Gowdy Jr. - Master Storyteller, Nati...
05/12/2025
SVG Sit-Down: Veritone's Sean King on the Power of Mining Video, Audio DataThe company's Data Refinery offers users total control and governance over da...
05/12/2025
Platinum White Paper: Inside the Nashville Predators' Unified, Flexible, Sca...
05/12/2025
Netflix Reaches Agreement To Acquire Warner Bros. Following Planned WBD SplitThe deal does not include WBDs sports assets like TNT Sports (US, UK, LatAm), Euros...
05/12/2025
FOX Sports Returns to Indianapolis for Primetime Broadcast of Big Ten Championsh...
05/12/2025
SVG Summit 2025 Preview: Digital Engagement & Monetization Workshop Tackles the ...
05/12/2025
Atlanta United Lights Up New Emory Healthcare Studio With First Live Broadcast f...
05/12/2025
As Messi Takes the Pitch, MLS, Apple, NEP Roll Out Largest MLS Cup Production Ev...
05/12/2025
ESPN Enters College Football's Most Intense Month With Elevated Workflows fo...
05/12/2025
It's about that time! Awards season is in full swing, and the Film Independe...
05/12/2025
Every year, Spotify Wrapped offers a personalized look back at the audio that defined your year. It's a snapshot of your listening habits, designed to tell ...
05/12/2025
In 2025, Spotify's EQUAL, GLOW, and RADAR programs celebrated women, LGBTQIA , and emerging artists who turned moments into milestones. From breaking record...
05/12/2025
In our latest blog, we explain how Wi-Fi 7 rollouts can drive consumer loyalty with value-add services such as consumer cybersecurity. We also explore how this ...
05/12/2025
LOS ANGELES Netflix announced it has entered into an agreement to acquire the assets of Warner Bros. for $82.7 billion....
05/12/2025
NEW YORK Nielsens Gracenote has launched Gracenote Content Connect, a new ad platform that provides agencies, brands, supply-side platforms (SSPs) and demand-si...
05/12/2025
NEW YORK In an most important update to the workings of deal-based programmatic advertising, IAB Tech Lab has released version 1.0 of its Deals API for public c...
05/12/2025
NEW YORK Pass the turkey. Pass the stuffing. Pass the cranberry sauce. All are common requests of Americans celebrating Thanksgiving Day with family and f...
05/12/2025
NEW YORK Iris, the new cloud-connected camera control platform, has officially launched with features that turn virtually any PTZ camera into a software-connect...
05/12/2025
HOLLYWOOD, Calif. Netflix announced today that it has entered into an agreement to acquire the assets of Warner Bros. for $82.7 billion....
05/12/2025
NEW YORK Iris, the new cloud-connected camera control platform, has officially launched with features that turn virtually any PTZ camera into a software-connect...
05/12/2025
WASHINGTON The Federal Communications Commission has approved AT&T's $1.02 billion acquisition of spectrum from UScellular in a decision that was issued sho...
05/12/2025
The Best Coldplay Songs: 21 Tracks That Shoot for the Stars From Yellow to Viva La Vida, Fix You to Paradise, this playlist goes back to the start.
December ...
05/12/2025
Zafris Lecture Series Brings Nabil Ayers to Berklee The 32nd annual James G. Zafris Distinguished Lecture series was held on Thursday, November 13, with guest...
05/12/2025
Introducing New Perks to Help You Get Even More from LinkedIn Premium Published on Dec 5, 2025 Categories: Company News, Product News
LinkedIn Corporate Co...
05/12/2025
Friday 5 December 2025
A new Game of Thrones Tale: Official trailer for Sky Exc...
05/12/2025
Back to All News
Don Lee, Lee Jin-uk, and Lalisa Manobal to Star in Netflix Act...
05/12/2025
Tis the season of giving once again and this year we've taken our Give Back Fridays' concept and turned it on its head.
In the autumn we were approach...
05/12/2025
Brayden Gogis doesn't remember a time when he wasn't completely fixated on games in all forms. In preschool, when they asked us to dress up as what we ...
05/12/2025
The Grinch steals the spotlight as the theme for The Late Late Toy Show 2025
Tune in tonight at 9:35pm on RT One and worldwide on RT Player
#LateLateToyShow...
05/12/2025
RT Announces New Presenters of Flagship News Programmes
New RT Six One News co-presenter Tommy Meskill
Sarah McInerney & Justin McCarthy join Morning Ir...
04/12/2025
ToolsOnAir Blackmagic Design HyperDeck Event Presets for just:in mac pro 2025 & ...
04/12/2025
ToolsOnAir AJA Ki Pro Event Presets for just:in mac pro 2025 & just:in linux
More Details:Starting with version 5.5, both just:in mac pro and just:in linux sol...
04/12/2025
Wangu Kanuri from Kenya and Godwin Asediba from Ghana are two of this years finalists for Thomsons Young Journalist of the Year Award. The pair are runners-up i...
04/12/2025
SVG Sit-Down: ProximaVision's Claudio Lisman on Why Tethered Drones Could Be...
04/12/2025
SVG Campus Shot Callers: Imry Halevi, Senior Associate Director of Athletics, Co...
04/12/2025
Platinum White Paper: LiveU Lightweight Sports Production: A Step Change in Spor...
04/12/2025
London to Riyadh: DAZN brings the boxing glamour to new production levels for Be...
04/12/2025
Analysis: Paramount bets on the battering ram' with Champions League play By Callum McCarthy, Editor-at-Large
Tuesday, December 2, 2025 - 10:12
Print ...
04/12/2025
Space City Home Network Launches SCHN DTC App for Astros and RocketsThe Rockets and Astros were previously the lone NBA and MLB teams without a DTC appBy Jason...
04/12/2025
SVG Summit 2025 Preview: Content Workflows Workshop Spotlights Evolution of Spor...
04/12/2025
New Sponsor Spotlight: Geotech's Patrick Wambold On the Unreal Engine Revolu...
04/12/2025
Curt Gowdy Jr. - Master Storyteller, Nationally and RegionallyBy Jason Dachman, Editorial Director, U.S.
Thursday, December 4, 2025 - 1:52 pm
Print This Sto...
04/12/2025
(L-R) Rebecca Lichtenfeld, Mohammadreza Eyni, Sara Khaki, and Judith Helfand att...
04/12/2025
SBS launches Future Frames initiative to support emerging First Nations video ed...
New strategy for cancer therapy spells double trouble for tumors Scripps Research scientists have found a clever way to combine two cellular defects and kill aggressive cancer cells.
